N,N-dimethyltryptamine, usually shortened to DMT, is being investigated as a rapidly acting intervention for depression. Its brief acute effects under some administration protocols could reduce the time spent in an altered state compared with oral psilocybin or LSD. Early clinical findings are encouraging, but a shorter experience does not remove the need for assessment, psychological support, medical monitoring or continuing care.
The duration of intoxication, the length of the clinical appointment and the duration of any antidepressant benefit are separate questions. None can be inferred reliably from the others.
On this page
- DMT, 5-MeO-DMT and ayahuasca are different interventions
- What the controlled depression evidence shows
- What inhaled DMT adds to the picture
- How long might improvement last?
- Safety extends beyond the peak experience
- Medication and preparation cannot be generalised from one protocol
- The role of psychological support
- Where DMT fits in depression care
DMT, 5-MeO-DMT and ayahuasca are different interventions
N,N-DMT is a serotonergic psychedelic. Intravenous formulations allow a defined preparation to be studied with controlled administration and observation. A phase 1 trial in 32 healthy, psychedelic-naïve participants examined intravenous SPL026 with psychological support; its purpose was principally to characterise tolerability and select a regimen for subsequent clinical research.1
5-MeO-DMT is a different molecule, also known as mebufotenin. It has its own pharmacology and development programmes. For example, a 2026 randomised trial of the inhaled formulation GH001 in 81 patients with treatment-resistant depression reported an antidepressant effect at day eight. That finding is evidence about GH001, not about N,N-DMT or every substance described informally as DMT.2
Ayahuasca is a preparation containing DMT together with other constituents, including compounds that inhibit monoamine oxidase. Those additional constituents change the intervention. A controlled ayahuasca trial in depression therefore cannot establish the efficacy or interaction profile of intravenous or inhaled N,N-DMT alone.3
| Intervention | Important distinction | Evidence cannot automatically establish |
|---|---|---|
| N,N-DMT | Effects depend on preparation and route of administration | The effectiveness of another DMT-related product |
| 5-MeO-DMT | A distinct psychoactive molecule | N,N-DMT’s benefits, risks or medication compatibility |
| Ayahuasca | A combination containing DMT and additional active constituents | The effects of isolated DMT |
| Psilocybin | A separate drug with a different clinical evidence base | That the same treatment schedule or outcomes apply to DMT |
What the controlled depression evidence shows
A 2026 phase IIa trial randomised 34 adults with moderate-to-severe major depression to intravenous DMT or placebo, with psychological support. At two weeks, the DMT group had a 7.35-point greater reduction on the Montgomery–Åsberg Depression Rating Scale. The 95% confidence interval ranged from 1.08 to 13.62 points in favour of DMT.4
This is a promising controlled signal from a small sample. Blinding integrity and expectation were not assessed, the sample lacked ethnic diversity, and people with a history of serious suicide attempts were excluded. These features limit the confidence with which the result can be applied to a broader clinical population.4
The useful inference is specific: a defined DMT intervention with support reduced depression ratings more than placebo with support over the measured period. It does not establish a universal response, a cure, or superiority to another active treatment. A person’s own treatment choices require more information than the average difference between two small groups.
What inhaled DMT adds to the picture
A 2025 open-label study examined vaporised N,N-DMT in 14 people with treatment-resistant depression. Depression ratings improved rapidly and remained below baseline during follow-up to three months. Because there was no placebo or active-treatment comparison group, the observed changes cannot be attributed entirely to DMT.5
Ten participants were taking antidepressants. That experience is useful preliminary information, but a small study without observed toxicity cannot establish the safety of all antidepressant combinations. The identity of the medicine, clinical history and administration protocol still matter.5
Intravenous and inhaled delivery should not be treated as clinically interchangeable. A formulation, route and clinical setting define what was actually tested. Even when the active molecule is the same, changing the speed of exposure or the support provided may alter the experience and the balance of benefit and harm.
How long might improvement last?
After the controlled phase of the 2026 trial, participants could receive open-label DMT. Improvement persisted during later follow-up, but there was no continuing placebo comparison. The absence of a significant difference between one and two administrations did not establish equivalence or an optimal retreatment schedule.4
A low depression score at a later appointment does not prove uninterrupted remission between visits. Further psychotherapy, medicines, life events and changes in sleep or substance use may also influence the course. Follow-up needs to record these events so that improvement is understood in its clinical context.
Relapse planning should remain practical. A patient needs to know which changes should prompt review and how to obtain help. Continuing care can include established psychological or pharmacological treatment; seeking further help does not invalidate an earlier improvement or mean that the psychedelic experience was handled incorrectly.6
Safety extends beyond the peak experience
The healthy-volunteer SPL026 study reported no serious adverse events. Its participants were medically screened and received support from two therapy-team members. This is informative about the studied setting, not a guarantee of safety in people with complex illness or in unsupervised use.1
A rapid onset can leave little time to adjust to major perceptual and emotional changes. Preparation should therefore address uncertainty as well as hoped-for benefit. The person should understand who will remain present, how distress will be handled and how to report difficulties after leaving the service.
Medical and psychiatric review also needs to consider cardiovascular vulnerability, previous mania or psychosis, current medication, other substance use and the person’s capacity to engage with the proposed programme. These are dimensions of individual assessment, not a self-administered eligibility test. General psychedelic-care guidance emphasises screening, informed consent, professional boundaries and follow-up, although recommendations developed for psilocybin cannot substitute for DMT-specific evidence.7
Continuing panic, severe sleep disruption, marked mood deterioration or difficulty distinguishing experience from external reality warrants assessment. Immediate danger or inability to remain safe requires emergency care. A short drug exposure does not justify dismissing symptoms that last longer.
Medication and preparation cannot be generalised from one protocol
A treatment plan should identify the exact substance and preparation being proposed. In particular, an ayahuasca-containing preparation should not be assumed to share the medication compatibility of a study of isolated DMT. Its additional active constituents are part of its pharmacology.3
Any proposed change to an established prescription needs a separate discussion with the prescriber. Withdrawal can produce symptoms that resemble deterioration or a reaction to a new intervention. NICE’s depression guidance supports planned, monitored reduction when stopping antidepressants; it does not support abrupt discontinuation to prepare for an unsupervised psychedelic experience.6
The role of psychological support
Support provides more than reassurance during intoxication. It can help the person form realistic expectations, communicate discomfort and consider afterwards whether any insights are useful in daily life. Clinical integration should permit uncertainty and disagreement rather than treating vivid experiences as verified memories or instructions.
Harm reduction and integration work can also be appropriate after an unwanted or difficult experience. The purpose is to support recovery and address impairment; it does not require endorsement of the original use or encouragement to repeat it.8
Where DMT fits in depression care
Persistent depression deserves a review of diagnosis, treatment adequacy, tolerability and the person’s priorities. Established further-line treatments remain available, and severe deterioration should not be left untreated while someone waits for access to an investigational intervention.6
DMT’s potential advantage is a shorter acute intervention, not a demonstrated reduction in every aspect of treatment burden. Claims of lower cost, easier delivery or equal effectiveness to longer-acting psychedelics need direct evaluation. The clinically relevant outcome is a sustained improvement in symptoms and functioning with acceptable harm, supported by care that remains available after the experience has ended.
References
- James E, Erritzoe D, Benway T, et al. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Front Psychiatry. Published 11 January 2024;14:1305796. doi:10.3389/fpsyt.2023.1305796.
- Cubała WJ, Bajbouj M, Bauer M, et al. GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83:561–569. doi:10.1001/jamapsychiatry.2026.0096.
- Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49:655-663. doi:10.1017/s0033291718001356.
- Erritzoe D, Barba T, Benway T, et al. A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nat Med. 2026;32:591–598. doi:10.1038/s41591-025-04154-z.
- Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology. 2025;50:895–903. doi:10.1038/s41386-025-02091-6.
- National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). Recommendations; accessed 11 October 2026.
- Hosein MM, Reid MJ, Walser S, et al. Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds. EClinicalMedicine. 2025;89:103517. doi:10.1016/j.eclinm.2025.103517.
- Gorman I, Nielson EM, Molinar A, et al. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front Psychol. 2021;12:645246. doi:10.3389/fpsyg.2021.645246.